News
April 22, 2021
MNG is Transitioning to Labcorp's New Brand
MNG specimen collection kits will be transitioning to Labcorp's brand.
June 19, 2020
Amino Acid Assay Update
Effective July 27, 2020 the MNG amino acid assays, Test Codes MET01, MET02, and MET03 will be performed by our Parent company, LabCorp, in its Burlington, NC laboratory.
October 24, 2019
MNG Moves To Exome-Backbone Sequencing
MNG is excited to announce the launch of 15 new next-generation sequencing (NGS) panels. In an effort to meet the needs of our clients, we are introducing a Comprehensive Hearing Loss panel and a Comprehensive Vision Loss & Eye Disorders panel, both including mtDNA analysis.
October 24, 2019
MNG Moves To Exome-Backbone Sequencing
MNG is excited to announce the launch of 15 new next-generation sequencing (NGS) panels. In an effort to meet the needs of our clients, we are introducing a Comprehensive Hearing Loss panel and a Comprehensive Vision Loss & Eye Disorders panel, both including mtDNA analysis.
October 1, 2019
Discontinuation Of Tests MET22 And MET25, Folate Receptor Antibody Assay, In Plasma/Serum And CSF
Due to a manufacturer reagent change, MNG will discontinue testing for Folate Receptor Antibodies.
May 22, 2019
Discontinuation Of Test NC09
Succinic semialdehyde dehydrogenase (SSADH) deficiency is a disorder affecting GABA metabolism. This disorder is generally diagnosed by the finding of elevated levels of gamma hydroxybutyric acid (GHB) in urine using standard organic acid analysis.
November 12, 2018
MNG Answers™
MNG is driven to help our healthcare partners, patients, and families find the answers they need when it comes to a diagnosis. MNG has solutions allowing economical reflex options to further investigate negative or inconclusive results.
November 12, 2018
MNG Answers™
MNG is driven to help our healthcare partners, patients, and families find the answers they need when it comes to a diagnosis. MNG has solutions allowing economical reflex options to further investigate negative or inconclusive results.
August 24, 2018
MNG Announces New Test Updates
The most common mutation, seen in >95% of Friedreich ataxia (FRDA) patients, is a GAA triplet-repeat expansion in intron 1 of the FXN gene. Individuals with less than 500 repeats often have a later age of onset compared to patients with greater than 600 repeats.
July 17, 2018
MNG Laboratories™ Adds Complementary MtDNA Genome Analysis To ID/Autism NGS Panels
Recent studies[1][2] have suggested a connection between mitochondrial DNA (mtDNA) and autism. At MNG Laboratories™, we strive to offer a comprehensive portfolio of tests to provide your patients with the answers they need.
July 3, 2018
MNG Laboratories, Pronto Diagnostics Partner To Offer Clinical RNA Sequencing
MNG Laboratories, an Atlanta-based neurogenetic testing company, is pleased to announce that it has signed a Distribution Agreement with Pronto Diagnostics, a leading Israeli genomics company, to exclusively market its complete line of Clinical RNA Sequencing Services in Israel.
April 9, 2018
MNG Expands Global Reach With Several New Distributors
MNG Laboratories is pleased to announce the signing of several key international distributor agreements in Asia, Latin America and Eastern Europe.
April 9, 2018
MNG Expands Global Reach With Several New Distributors
MNG Laboratories is pleased to announce the signing of several key international distributor agreements in Asia, Latin America and Eastern Europe.
January 15, 2018
Significant Improvements Made To Our Dystonia Panel Portfolio
We are pleased to announce that we have made substantial improvements in our ability to search for and identify the known pathogenic variants likely to cause dystonia.